Findit, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
April 04, 2023 at 11:33 am
Share
Findit, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported revenue was USD 0.042159 million compared to USD 0.198584 million a year ago. Net loss was USD 0.078308 million compared to USD 0.096873 million a year ago.
BioRegenx, Inc., formerly Findit, Inc., operates as a holding company. The Company specializes in acquiring intellectual property (IP) and companies engaged in regenerative biotherapeutics and anti-aging research. Its primary focus involves acquiring and developing non-invasive medical and wellness devices capable of efficiently recording, storing, and analyzing datasets. The Companyâs patented technologies and solutions include GlycoCheck, a high-definition video imaging that analyzes five parameters of microvascular health non-invasively with an under the tongue test using patented technology; Endocalyx Pro, an all-natural, plant-based patented nutraceutical shown to restore, regenerate, and protect microvascular health. Clinically tested in multiple double-blind placebo studies, and DocSun, an artificial intelligence using three advanced facial recognition technologies that analyzes 21 vital signs and health indicators without physical contact.